JPRN-jRCT1031230452招募中1 期
Sugammadex dosing based on ideal or actual body weight in underweight patients.
Sato Hanae0 个研究点目标入组 32 人开始时间: 2023年11月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •BMI below 18.5
- •ASA-PS= 1-3
排除标准
- •ppatient who is allergic to muscle relaxants
- •patient who has neuromuscular diseases
- •patient who has moderate to severe liver function failure
- •Patients with hypoalbuminemia
- •Patients taking medications that affect the muscle relaxant effect
- •Patients who are deemed inappropriate as research subjects by the principal investigator
研究者
相似试验
招募中
不适用
Sugammadex dosing based on ideal or actual body weight in underweight patients.JPRN-UMIN000040550ihon University School of Medicine32
Unknown
3 期
Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular BlockadeNeuromuscular BlockadeNCT01855217St. Antonius Hospital25
已完成
3 期
Sugammadex-dosing in Bariatric PatientsNeuromuscular BlockadeNCT01570179Central Hospital, Nancy, France34
已完成
不适用
Sugammadex doses for effective dose - reaction comparative study for the reversal of neuromuscular blockade induced by rocuronium.Patients scheduled for elective surgery requiring general anesthesiaJPRN-UMIN000025218Department of Anesthesiology Nihon University School of Medicine40
已完成
2 期
Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese PatientsMorbid ObesityNCT02545595Poitiers University Hospital